LRLea Rubira

Lea Rubira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lea Rubira has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Beyond Phenylbutyric Acid: Evans Blue and Ibuprofen as Albumin- Binding Motifs for PSMA-Targeted Radioligand Therapy of Prostate Cancer

    by Cyril Fersing, Johanne Vanney, Jade Torchio, Stephane C. Renaud, Lea Rubira

    Introduction: Radioligand Therapy (RLT) targeting Prostate-Specific Membrane Antigen (PSMA) reshapes the therapeutic landscape of metastatic castration-resistant prostate cancer. However, the rapid systemic clearance of small-molecule radioligands directly affects circulation time and tumor exposure. Reversible albumin binding emerged as a practical strategy to extend circulation and modulate biodistribution. Among drug-derived Albumin-Binding Moieties (ABMs), Evans Blue (EB) and ibuprofen (Ibu) offer distinct approaches to improve pharmacokinetics and the therapeutic index. Methods: This review analyzes the design, synthesis, structure-activity relationships, and evaluation of PSMA radioligands incorporating EB- or Ibu-derived ABMs. Preclinical and clinical literature was examined, with emphasis on translational candidates. Results: EB confers strong albumin binding and markedly prolongs tumor residence, whereas Ibu enables more finely tunable interactions with albumin. The impact of linker, radionuclide, and albumin affinity on biodistribution, dosimetry, and therapeutic efficacy are essential to consider. Available data suggest that albumin binding is a tunable pharmacokinetic parameter rather than a binary property. Clinical experience with EB-PSMA-617 and SibuDAB demonstrates that increasing tumor absorbed dose through prolonged circulation is achievable but may increase irradiation of kidneys, bone marrow, and salivary glands. Discussion: These findings support the hypothesis that moderately strong, tunable albumin binding offers the most favorable therapeutic window. Stereochemical optimization of Ibu-derived ABMs and linker engineering illustrate how subtle structural changes can rebalance tumor uptake, clearance, and safety. Future radiopharmaceutical design will likely rely on iterative structure- pharmacokinetic optimization and dosimetry to define optimal albumin affinity. Conclusion: Overall, ABMs appear to be central tools for the design of next-generation PSMA radioligands and other radiopharmaceuticals.


  • Open Access

    Radionuclide Therapy of Prostate Cancer Using PSMA Ligands with a 4-Phenylbutyric Acid-Derived Albumin Binder: Recent Chemical and Clinical Advances

    by Johanne Vanney, Jade Torchio, Lea Rubira, Stephane C. Renaud, Cyril Fersing

    Radioligand therapy (RLT) targeting the prostate-specific membrane antigen (PSMA) has become a key treatment modality for metastatic castration-resistant prostate cancer. However, the rapid clearance and suboptimal tumor uptake of current smallmolecule PSMA ligands limit their therapeutic index. Incorporating reversible albuminbinding moieties (ABM), particularly 4-phenylbutyric acid (PBA)-derived groups, has emerged as a powerful strategy to modulate pharmacokinetics by prolonging systemic circulation, enhancing tumor uptake, and improving radiation dose delivery. This review summarizes the chemical and translational advances of PSMA-targeting radiopharmaceuticals integrating PBA-type ABM. It details structure-activity relationships governing albumin affinity and linker design across all major chemical series. Emphasis is placed on the most clinically advanced candidates, i.e. PSMA-Trillium, HTK03170, Ludotadipep, P17-088, and CTT1403, highlighting their pharmacokinetics, tumor targeting, safety profiles, and early clinical outcomes. Key determinants of in vivo performance, including affinity for albumin and PSMA, polarity and length of linker elements, are examined in the context of tumor-to-kidney dose ratios and therapeutic efficacy. Collectively, PBA-derived ABM have proven highly effective but require careful tuning, as excessive albumin binding could lead to prolonged hematologic exposure and kidney irradiation, whereas insufficient affinity reduces therapeutic gains. The most successful ligands achieve a balanced interplay between albumin binding, PSMA affinity, and controlled renal clearance. As next-generation α- and β-emitters enter clinical development, optimized ABM-containing radiopharmaceuticals are expected to deliver higher tumor doses with improved safety, supporting their growing role in precision therapy for advanced prostate cancer.


  • Open Access

    “One Method to Label Them All”: A Single Fully Automated Protocol for GMP-Compliant 68Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617

    by Juliette Fouillet, Charlotte Donzé, Emmanuel Deshayes, Lore Santoro, Léa Rubira, Cyril Fersing

    Background: Prostate-specific membrane antigen (PSMA) is an ideal target for molecular imaging and targeted radionuclide therapy in prostate cancer. Consequently, various PSMA ligands were developed. Some of these molecules are functionalized with a chelator that can host radiometals, such as 68Ga for PET imaging. The 68Ga radiolabeling step benefits from process automation, making it more robust and reducing radiation exposure. Objective: To design a single automated radiolabeling protocol for the GMP-compliant preparation of [68Ga]Ga-PSMA-11, transposable to the production of [68Ga]Ga-PSMA-617 and [68Ga]Ga-PSMA-I&T. Methods: A GAIA® synthesis module and a GALLIAD® generator were used. Radio-TLC and radio-HPLC methods were validated for radiochemical purity (RCP) determination. Three [68Ga]Ga-PSMA-11 validation batches were produced and thoroughly tested for appearance and pH, radionuclide identity and purity, RCP, stability, residual solvent and sterility. Minimal modifications were made to the reagents and disposables for optimal application to other PSMA ligands. Results: [68Ga]Ga-PSMA-11 for clinical application was produced in 27 min. The 3 validation batches met the quality criteria expected by the European Pharmacopoeia to allow routine production. For optimal transposition to PSMA-617, the solid phase extraction cartridge was changed to improve purification of the radiolabeled product. For application to PSMA-I&T, the buffer solution initially used was replaced by HEPES 2.7 M to achieve good radiochemical yields. Residual HEPES content was checked in the final product and was below the Ph. Eur. threshold. Conclusion: A single automated radiolabeling method on the GAIA® module was developed and implemented for 68Ga radiolabeling of 3 PSMA ligands, with slight adjustments for each molecule.